The objectives of this Phase III study were to evaluate the safety , tolerability , and efficacy of saroglitazar ( ZYH1 ) 2-mg and 4-mg tablets ( Lipaglyn ; Zydus Cadila , Ahmedabad , India ) compared with placebo in patients with diabetic dyslipidemia who are not controlled with atorvastatin 10mg therapy .
